Thermo Fisher Scientific (TMO) Q1 FY26 earnings call: guidance and Q&A

Investors are concerned about the acceleration needed to hit full-year guidance, given Q1's 1% organic growth and Q2's projected 3%. What assures management of this ramp?

Marc Casper stated that the ramp does not assume a change in underlying market conditions but is driven by comparable days and easier comparisons in Analytical Instruments. Jim Meyer added that Q1 had one less selling day and Q2 benefits from a significant comparable change in Analytical Instruments, while Pharma Services will have stronger growth in H2.

“the ramp is not really assuming a change in the underlying market conditions. This happens to do with comparable days, things of that sort.”

asked by Michael Ryskin · answered by Marc Casper

How did PPD perform in the quarter, especially given a peer's light bookings? Is biotech funding translating into spending, and what's the early feedback on Clario?

Clinical Research had an excellent quarter with strong organic revenue and authorizations growth, indicating continued share gain. Biotech funding is improving, and sentiment is strengthening. Clario, recently closed, is receiving positive customer feedback, particularly for its technology in bringing major endpoints together for clinical trials.

“Clinical Research has had an excellent quarter. And whether you're starting to say sequentially, how is the business progressing nice step-up in organic growth. But then when you look at it year-over-year, really nice growth organically, both in revenue and authorizations, the customers really value our capabilities.”

asked by Tycho Peterson · answered by Marc Casper

How is AI influencing customer spending behavior across business segments, and how might this affect future instrument development, especially regarding scale, automation, and data connectivity?

Marc Casper highlighted AI's role in accelerating scientific discovery and improving drug development ROI, leading to more pipeline products and increased biotech funding. He noted that customers need instruments to be more automated and data-ready for large-scale biological data generation, a trend Thermo Fisher has been addressing in its R&D roadmaps for years.

“you're seeing experimentation scale up and will scale up in areas that it would never have happened in the past, right, which is just large-scale generation of biologic information to effectively create biology models.”

asked by Jack Meehan · answered by Marc Casper

Given management's prior goal to retire risk throughout the year, what risks have been retired, and what's the rationale behind not flowing 100% of the Q1 operational beat to the full-year EPS guidance?

Marc Casper stated that Q1's performance, aligning with expectations, retired risk. The operational beat was strong, but a portion was held back in guidance as a cushion for potential future inflation volatility, though the team is focused on offsetting it.

“The only reason we didn't do 100% of that is there's volatility, as Jim said, in inflation. Nobody has a crystal ball exactly how it is. What I do know is our team is fully focused on offsetting it with all the levers.”

asked by Daniel Arias · answered by Marc Casper

What is the confidence level that reshoring will remain a tailwind, and what is Thermo Fisher's activity level in this area?

Marc Casper confirmed reshoring is a "nice tailwind" for 2027 and 2028, with secured business in CDMO and brownfield bioproduction facilities. He noted President Trump's visit to a drug product site as an example of momentum and signed contracts, increasing confidence in future revenue.

“In bioproduction, we expect that the revenue is largely a '27 and '28 activity. We've won some business already in terms of in kind of industry parlance, brownfield facilities that are scaling up.”

asked by Matthew Larew · answered by Marc Casper

How did China perform across the portfolio, particularly in pharma, and is growth expected to return this year?

China, representing 7.5% of revenue, saw a low single-digit decline in Q1 with muted conditions. Pharma and biotech performed well. Marc Casper's recent visit made him incrementally more positive, noting Chinese innovators value Thermo Fisher's technology for competitive advantage. No meaningful growth is assumed for China in 2026, but it represents potential upside long-term.

“I actually left China incrementally more positive coming out, particularly as what I did see is that China pharma and biotech customers, the innovators see the value in doing more work with a company like us because when they're competing with another Chinese company, actually, our technology and capabilities is a differential advantage for them.”

asked by Casey Woodring · answered by Marc Casper